In this episode, we delve into a groundbreaking study published in 2026 that challenges long-held beliefs about the genetic causes of vision impairment. The research reveals that many genes linked to inherited eye diseases rarely result in vision loss, prompting a reevaluation of genetic counseling and testing practices.

Next, we explore the new guidelines released by the European Medicines Agency and the U.S. FDA for integrating artificial intelligence into drug development. These principles focus on ethical alignment, human-centric design, and maintaining patient safety while fostering innovation.

We then shift to insights from JPM Week in San Francisco, where biotech leaders discussed the industry's shift from market risk to geopolitical challenges, emphasizing the need to adapt strategies in response to global events.

Meanwhile, Eli Lilly and NVIDIA have announced a $1 billion partnership to establish an AI co-innovation lab, aiming to revolutionize drug development and clinical processes through advanced AI technologies.

Finally, Fresenius Kabi and TQ Therapeutics have teamed up to enhance cell and gene therapy accessibility, integrating cutting-edge cell selection technology to streamline production and accelerate treatment availability for patients.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.managedhealthcareexecutive.com/view/5-key-takeaways-on-most-favored-nations-pricing-from-mjh-life-sciences-webinar
• https://pharmaphorum.com/news/ema-and-fda-agree-principles-ai-drug-development
• https://medcitynews.com/2026/01/how-does-geopolitics-affect-the-life-sciences-industry-3-executives-weigh-in/
• https://www.mobihealthnews.com/news/jpm-nvidia-and-eli-lilly-announce-co-innovation-ai-lab
• https://www.biospace.com/press-releases/fresenius-kabi-tq-therapeutics-announce-cell-therapy-technology-agreement

In this episode, we explore key developments in the global life sciences and biotech sectors. Telangana is set to unveil its Next-Generation Life Sciences Policy 2026–2030 at the World Economic Forum, aiming to position itself as a top global life sciences hub. The U.S. biotech sector faces challenges from inconsistent funding and regulations, risking its global leadership. Lilly and NVIDIA announce a $1 billion AI-focused co-innovation lab in South San Francisco, while Illumina launches the Billion Cell Atlas to enhance AI-driven drug discovery. Hippocratic AI acquires Grove AI to boost its life sciences capabilities. Changes to the UK's Voluntary Pricing and Access Scheme are underway following a UK-US trade deal. Lastly, Rosanna Zhang from ACROBiosystems discusses the use of organoids in neuroscience research, offering new insights into brain disorders.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.metroindia.net/news/articlenews/telangana-to-unveil-next-gen-life-sciences-policy-at-davos-34250
• https://www.biospace.com/policy/opinion-trump-must-make-biotech-innovation-a-national-priority
• https://www.drugdiscoverytrends.com/lilly-and-nvidia-unveil-1b-co-innovation-lab-in-sf/
• https://www.genengnews.com/topics/drug-discovery/ai-and-drug-discovery-get-a-boost-from-illuminas-billion-cell-atlas-release
• https://pharmaphorum.com/news/hippocratic-ai-builds-life-sciences-grove-ai-buy
• https://pharmaphorum.com/market-access/changes-uks-vpag-non-submissions-should-be-key-metric-impact
• https://www.news-medical.net/news/20260114/Disease-responsive-nanoparticles-enable-ghrelin-mRNA-therapy-in-osteoarthritis.aspx